Search for: "AstraZeneca, AB"
Results 1 - 20
of 92
Sorted by Relevance
|
Sort by Date
7 Sep 2017, 9:59 pm
AstraZeneca AB affirming the patentability of all challenged claims. [read post]
3 Feb 2014, 7:11 pm
Astrazeneca AB at *5. [read post]
16 Apr 2015, 9:59 pm
As set forth in the opinion, AstraZeneca's lawsuit against Apotex was part of the "second wave" of ANDA litigation, wherein the District Court apportioned into two sets of four defendants from the eight ANDA filers sued by AstraZeneca in the Southern District of New York starting at the end of the last century. [read post]
30 Dec 2013, 8:50 pm
Noonan -- A classic example of product "evergreening" is how AstraZeneca used its experience with its omeprazole franchise (sold for over a decade as Prilosec®) to promote an alternative form of the drug, Nexium® (particularly, the S-omeprazole enantiomer) as "the little purple pill." [read post]
27 Oct 2013, 9:55 pm
Astrazeneca AB et al. v. [read post]
8 Dec 2013, 8:02 pm
Astrazeneca AB et al. v. [read post]
26 May 2012, 8:41 pm
Apotex Pty Ltd v AstraZeneca AB [2011] FCA 1520 (14 December 2011) Apotex Pty Ltd v AstraZeneca AB (No 2) [2012] FCA 142 (28 February 2012) Watson Pharma Pty Ltd v AstraZeneca AB [2012] FCA 200 (9 March 2012) Apotex Pty Ltd v AstraZeneca AB (No 3) [2012] FCA 265 (23 March 2012) AstraZenenca’s cholesterol drug CRESTOR will remain without generic competition in the Australian market for the foreseeable future, following… [read post]
25 Mar 2012, 9:25 pm
AstraZeneca AB et al v. [read post]
13 Nov 2015, 2:42 pm
Robinson in AstraZeneca AB, et al. v. [read post]
21 Nov 2015, 5:54 am
Robinson in AstraZeneca AB, et al. v. [read post]
16 Jul 2011, 1:42 am
Ranbaxy (UK) Ltd. v AstraZeneca AB [2011] EWHC 1831 (Pat) (15 July 2011) raises an interesting point on the interpretation of claims. [read post]
7 Aug 2011, 8:36 pm
Astrazeneca AB et al. v. [read post]
11 Mar 2012, 3:32 pm
Apotex Pty Ltd v AstraZeneca AB (No 2) [2012] FCA 142 (28 February 2012) Watson Pharma Pty Ltd v AstraZeneca AB [2012] FCA 200 (9 March 2012) Interlocutory injunctions – prima facie case – balance of convenience – whether additional evidence provides grounds to vary previous findings At least five Australian pharmaceutical manufacturers are now ready to launch generic versions of cholesterol-lowering drug CRESTOR, while being barred from… [read post]
31 Mar 2011, 7:46 am
-based AstraZeneca plc announced that it will pay the Internal Revenue Service $1.1 billion to settle all transfer pricing issues for 2000-10, according to a March 28 statement released by the company.Astrazeneca also noted that the company settled with the IRS on the related valuation matter of a 2000 restructuring that followed the 1999 merger of Astra AB and Zeneca Group plc.In addition to the IRS settlement, the company said that the U.S. and U.K. [read post]
24 Mar 2013, 8:01 pm
AstraZeneca AB et al. v. [read post]
31 Aug 2014, 9:05 pm
AstraZeneca AB v. [read post]
16 Aug 2009, 9:58 pm
Breath Ltd. 1:09-cv-04115; filed August 12, 2009 in the District Court of New Jersey • Plaintiffs: Astrazeneca LP; Astrazeneca AB • Defendant: Breath Ltd. [read post]
4 Jan 2022, 6:00 am
Cir. 2021) 2021-1729 AstraZeneca AB and AstracZeneca Pharmacueticals LP (AstraZeneca) sued Mylan Pharmaceuticals Inc. and Kindeva Drug Delivery L.P. [read post]
15 May 2012, 3:12 pm
457/10 P AstraZeneca AB and AstraZeneca plc v European Commission can be read in full here, The IPKat can't help admire the zeal and zest with which AstraZeneca has fought its corner, first on the question of liability and then on the quantum of the fine. [read post]
16 Aug 2014, 11:39 pm
AstraZeneca AB v Apotex Pty Ltd [2014] FCAFC 99 (12 August 2014)An expanded panel of five judges of the Federal Court of Australia has held that two patents owned by AstraZeneca relating to the cholesterol-lowering drug marketed as CRESTOR (active ingredient rosuvastatin) are invalid. [read post]
